Skip to main content

Cytokine and Cytokine Receptor-Based Immunotherapies: Updates, Controversies, Challenges, and Future Perspectives

120kviews
Editorial26 July 2022
Editorial: Cytokine and cytokine receptor-based immunotherapies: Updates, controversies, challenges, and future perspectives

Cytokines are critical in mediating intercellular communications and shaping the tumor microenvironment. Scientific advances made in the last few decades have revealed pivotal roles for specific cytokines in regulating innate and adaptive immune responses against cancer, with some molecules demonstrating clear anti-tumor or pro-tumor effects and others displaying pleiotropic effects [1,2]. In this collection of five review articles and two research articles, 41 authors have contributed to this research topic, discussing the challenges, controversies and future perspectives for cytokine and cytokine receptor-based immunotherapies.A number of immune-stimulatory cytokines, including IFN-α, GM-CSF, IL-2, IL-7, IL-12, IL-15, IL-18 and IL-21, have been explored as anti-tumor agents, among which IFN-α and IL-2 are approved by FDA for treating various malignancies [3,4]. While many of these antitumor cytokines achieved limited success as single therapeutic agents in clinical trials, their immune-stimulatory properties have engaged strong interest in using these cytokines in combination therapies with checkpoint inhibitors and other therapies. Atallah-Yunes and Robertson (*link) review the biology and recent advances of several immune-stimulatory cytokines, with a specific focus on studies in lymphoma.Conversely, T helper 2 cytokines like IL-4 and IL-13 are pro-tumor cytokines and their cognate receptors have been recognized as novel therapeutic targets [5]. Due to the overexpression of interleukin-13 receptor subunit alpha-2 (IL-13Rα2) on a variety of tumors and its association with tumor progression, this receptor has received interest as a target of cancer immunotherapy. Knudon et al. (*link) review therapeutic approaches to targeting IL-13Rα2.Receptor targeting peptides, ligands engineered for selectivity, and antibodies coupled to cytotoxic molecules have generated promising results in pre-clinical models and some clinical trials. CAR-T cells targeting IL-13Rα2 have generated mixed results due to poor persistence and selection for IL-13Rα2-negative tumor recurrence. IL-13Rα2 has been targeted as one of several antigens in multi-target cancer vaccines and IL-13Rα2 therapeutics are likely to work better in combination therapies incorporating other modalities.The IL-6 family cytokine, cardiotrophin-like cytokine factor 1 (CLCF1), acts on the tumor microenvironment to promote tumor cell stemness and a pro-tumorigenic microenvironment [6,7]. Jiang et al. (*link) used bioinformatic analysis to show increased CLCF1 expression in glioma patients, a feature that correlated with poor survival outcome in two cohorts and had greater prognostic use than IL-6. CLCF1 correlated positively with higher regulatory T cell (Treg) levels and higher expression of immune checkpoint markers (PD1/ PD-L1). However, patients with low CLCF1 were more likely to respond to anti-PD-1 therapy. This suggests that additional factors act in the microenvironment to regulate immunity.Notably, many pleiotropic cytokines display complicated or opposing roles in cancer, with many exhibiting anti-tumor and pro-tumor activities in a stage-dependent manner. This may be attributed to dynamic changes in intratumoral immune cells [8] and intricate positive and negative feedback signaling networks within the tumor microenvironment [9,10]. Liu et al.(*link) review the literature surrounding the respective roles of transforming growth factor beta (TGF-β) and tumor necrosis factor (TNF-α) in tumor formation and the combinational effects of the two cytokines in various aspects of tumorigenesis, including cell proliferation, apoptosis, inflammation, extracellular matrix and genomic instability. While TGF-β and TNF-α display synergistic effects in certain settings and certain cell types, they antagonize each other in other conditions and different cell types. A yin-yang theory is proposed to describe the crosstalk effect between TGF-β and TNF-α, in which they restrict and balance each other.Chemokines and chemokine receptors play critical roles in leukocyte trafficking and the composition of tumor-infiltrating lymphocytes, as such, chemokine/chemokine receptors have been explored as anti-cancer therapeutic targets [11,12]. The C-C chemokine receptor type 2 (CCR2) is expressed by multiple cell types, including monocytes, immature dendritic cells, Tregs, endothelial cells and cancer cells [13]. CCR2 and its ligands mediate recruitment and polarization of suppressive myeloid cells [14,15], recruitment and activity of Tregs [16,17], and survival and invasion of tumor cells [13]. Fei et al. (*Link) review the role of CCR2 in these processes and outline strategies to target CCR2 for cancer immunotherapy. Targeting CCR2 is likely complicated by redundancies in chemokine and chemokine receptor networks. However, some studies suggest CCR2 antagonism may work better in combination with other therapies including chemotherapeutics, radiation, and checkpoint blockade. The chemokine (C-X-C motif) ligand 13 (CXCL13) and its receptor CXCR5 are among the key chemotactic factors regulating tumor-specific microenvironment in a context-dependent manner [18]. Zhang et al. (*link) conducted a comprehensive bioinformatic analysis of 33 human cancer datasets from The Cancer Genome Atlas (TCGA) to examine the correlation between CXCL13 expression and clinicopathological characteristics, prognosis, mismatch repair genes (MMRs), microsatellite instability (MSI), tumor mutation burden (TMB), immune cells infiltration, immune-related genes, and the role in tumor immunotherapy. The expression of CXCL13, validated in a local cohort, exhibited a dichotomy in modulating clinical outcomes, with a positive correlation in some cancer types and a negative correlation in others. The expression of CXCL13 also seems to be a good biomarker to predict treatment responses to the checkpoint blockade.Growth factors are a subtype of cytokines that control cell proliferation and/or differentiation. Colony-stimulating factor 1 (CSF-1) and its receptor (CSF-1R) are well-known for their roles in bone marrow homeostasis, particularly for the development, differentiation and activation of myeloid cells [19]. IL-34 is the second ligand for CSF-1R [20], which displays comparable biological activity in macrophage differentiation, but stronger impact on macrophage polarization as compared to CSF-1 [21]. Monteleone et al. (*link) review the role of IL-34/CSF-1R axis in the pathogenesis of colon cancer. They outline the role of IL-34 in controlling the growth of colorectal carcinoma and differentiation of tumor-associated macrophages. They also discuss the role of IL34/CSF-1R in promoting cancer resistance to chemotherapy and immunotherapy.Undoubtedly, cytokine and cytokine-receptor-based immunotherapies hold promise for cancer treatment. In addition to the discovery of new therapeutic targets, our collection highlights a future perspective of this research field in the development and optimization of combination therapies with checkpoint inhibitors and other novel therapies.

2,301 views

2 citations

REVIEW
28 June 2022
Targeting IL-34/MCSF-1R Axis in Colon Cancer
Giovanni Monteleone, 5 more and Irene Marafini

5,506 views

13 citations

MINI REVIEW
8 April 2022
Recent Advances in IL-13Rα2-Directed Cancer Immunotherapy

17,777 views

84 citations

REVIEW
5 January 2022
Duality of Interactions Between TGF-β and TNF-α During Tumor Formation
Zhi-wei Liu, 9 more and Yong-qi Liu

17,541 views

97 citations

CCR2 is predominantly expressed by monocytes/macrophages with strong proinflammatory functions, prompting the development of CCR2 antagonists to dampen unwanted immune responses in inflammatory and autoimmune diseases. Paradoxically, CCR2-expressing monocytes/macrophages, particularly in tumour microenvironments, can be strongly immunosuppressive. Thus, targeting the recruitment of immunosuppressive monocytes/macrophages to tumours by CCR2 antagonism has recently been investigated as a strategy to modify the tumour microenvironment and enhance anti-tumour immunity. We present here that beneficial effects of CCR2 antagonism in the tumour setting extend beyond blocking chemotaxis of suppressive myeloid cells. Signalling within the CCL2/CCR2 axis shows underappreciated effects on myeloid cell survival and function polarization. Apart from myeloid cells, T cells are also known to express CCR2. Nevertheless, tissue homing of Treg cells among T cell populations is preferentially affected by CCR2 deficiency. Further, CCR2 signalling also directly enhances Treg functional potency. Thus, although Tregs are not the sole type of T cells expressing CCR2, the net outcome of CCR2 antagonism in T cells favours the anti-tumour arm of immune responses. Finally, the CCL2/CCR2 axis directly contributes to survival/growth and invasion/metastasis of many types of tumours bearing CCR2. Together, CCR2 links to two main types of suppressive immune cells by multiple mechanisms. Such a CCR2-assoicated immunosuppressive network is further entangled with paracrine and autocrine CCR2 signalling of tumour cells. Strategies to target CCL2/CCR2 axis as cancer therapy in the view of three types of CCR2-expessing cells in tumour microenvironment are discussed.

36,861 views

233 citations